Pfizer and Protalix BioTherapeutics have submitted a Marketing Authorization Application to the EMA for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD), for the treatment of Gaucher disease. Taliglucerase alfa was granted orphan designation by the European Commission for this indication in March 2010. In November 2009, the two companies entered into an agreement to develop and commercialize taliglucerase alfa. Pfizer has exclusive worldwide licensing rights for the...